Walleye Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Walleye Capital’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,025	Closed	-$347	–	1597
2020 Q4	$347	Buy	+15,025	New	+$190K	0.02%	586

Walleye Capital's PRVL Position: Q1 2021 in Review

Walleye Capital sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 15,025 shares — an estimated $347 sold.

Walleye Capital first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $347 in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Walleye Capital reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Walleye Capital sold 15,025 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $347.
Walleye Capital first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Walleye Capital's Prevail Therapeutics Inc. Common Stock position peaked at $347 in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Walleye Capital's 13F filing for Q1 2021, filed 17 May 2021.